Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 6
Opinion
Video
Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC
Author(s):
Key Takeaways
- Darolutamide addition to ADT significantly improved progression-free survival in metastatic hormone-sensitive prostate cancer patients compared to placebo.
- The trial highlighted darolutamide's favorable safety profile, supporting its use in combination with ADT.
The panelist discusses how the ARANOTE trial demonstrated significant benefits of adding darolutamide to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer, showing improvements in radiographic progression-free survival and other key outcomes.
Video Content above is prompted by the following:
- Discuss the findings of the ARANOTE trial (NCT04736199), which compared the addition of darolutamide or placebo to androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Related Videos
Related Content
